業績一覧

2024

  1. Shimada S,Tanaka S. The chronicles of hepatocellular carcinoma classification: Subtyping, modeling, and treatment. Hepatology, 2024; 79(2):261-263.

2023

  1. Ishii T, Akiyama Y, Shimada S, Kabashima A, Asano D, Watanabe S, Ishikawa Y, Ueda H, Akahoshi K, Ogawa K, Ono H, Kudo A, Tanabe M, Tanaka S. Identification of a novel target of SETD1A histone methyltransferase and the clinical significance in pancreatic cancer. Cancer Science, 2023; 114(2):463-476.
  2. Yamamoto Y, Shimada S, Akiyama Y, Tsukihara S, Sugimoto R, Kabashima A, Tokunaga M, Kinugasa Y, Kawakami Y, Tanaka S. RTP4 silencing provokes tumor-intrinsic resistance to immune checkpoint blockade in colorectal cancer. Journal of Gastroenterology, 2023; 58(6):540-553.
  3. Yagi K, Shimada S, Akiyama Y, Hatano M, Asano D, Ishikawa Y, Ueda H, Watanabe S, Akahoshi K, Ono H, Tanabe M, Tanaka S. Loss of SFXN1 mitigates lipotoxicity and predicts poor outcome in non-viral hepatocellular carcinoma. Scientific Reports, 2023; 13(1):9449.
  4. Murota Y, Nagane M, Wu M, Santra M, Venkateswaran S, Tanaka S, Bradley M, Taga T, Tabu K. A niche-mimicking polymer hydrogel-based approach to identify molecular targets for tackling human pancreatic cancer stem cells. Inflammation and Regeneration, 2023; 43(1):46.
  5. Hatano M, Akiyama Y, Shimada S, Yagi K, Akahoshi K, Itoh M, Tanabe M, Ogawa Y, Tanaka S. Loss of KDM6B epigenetically confers resistance to lipotoxicity in nonalcoholic fatty liver disease-related HCC. Hepatology Communications, 2023; 7(10):e0277.

2022

  1. Shimada S, Tanaka S. Molecular targeted drugs, comprehensive classification and preclinical models for the implementation of precision immune oncology in hepatocellular carcinoma. International Journal of Clinical Oncology, 2022; 27(7):1101-1109.
  2. Kabashima A, Matsuo Y, Ito S, Akiyama Y, Ishii T, Shimada S, Masamune A, Tanabe M, Tanaka S. cGAS-STING signaling encourages immune cell overcoming of fibroblast barricades in pancreatic cancer. Scientific Reports, 2022; 12(1):10466.
  3. Asano D, Kudo A, Akahoshi K, Maekawa A, Murase Y, Ogawa K, Ono H, Ban D, Tanaka S, Tanabe M. Curative Surgery and Ki-67 Value Rather than Tumor Differentiation Predict the Survival of Patients with High-grade Neuroendocrine Neoplasms. Annals of Surgery, 2022; 276(2):e108-e113.

2021

  1. Kabashima A, Shimada S, Shimokawa M, Akiyama Y, Tanabe M, Tanaka S. Molecular and immunological paradigms of hepatocellular carcinoma: Special reference to therapeutic approaches. Journal of Hepato-Biliary-Pancreatic Sciences, 2021; 28(1):62-75.
  2. Akasu M, Shimada S, Kabashima A, Akiyama Y, Shimokawa M, Akahoshi K, Kudo A, Yamaoka S, Tanabe M, Tanaka S. Intrinsic activation of β-catenin signaling by CRISPR/Cas9-mediated exon skipping contributes to immune evasion in hepatocellular carcinoma. Scientific Reports, 2021; 11(1):16732.
  3. Zhang M, Sugita I, Komura D, Katoh H, Shimada S, Inazawa J, Tanaka S, Ishikawa S. Genomic landscape of a mouse model of diffuse-type gastric adenocarcinoma. Gastric Cancer, 2021; 25(1):83-95.
  4. Aramaki O, Takayama T, Moriguchi M, Sakamoto H, Yodono H, Kokudo N, Yamanaka N, Kawasaki S, Sasaki Y, Kubota K, Otsuji E, Tanaka S, Matsuyama Y, Fujii M. Arterial chemoembolisation with cisplatin versus epirubicin for hepatocellular carcinoma (ACE 500 study): A multicentre, randomised controlled phase 2/3 trial. European Journal of Cancer, 2021; 157:373-382.
  5. Taniai T, Shirai Y, Shimada Y, Hamura R, Yanagaki M, Takada N, Horiuchi T, Haruki K, Furukawa K, Uwagawa T, Tsuboi K, Okamoto Y, Shimada S, Tanaka S, Ohashi T, Ikegami T. Inhibition of acid ceramidase elicits mitochondrial dysfunction and oxidative stress in pancreatic cancer cells. Cancer Science, 2021; 112(11):4570-4579.

2020

  1. Yoshino J, Akiyama Y, Shimada S, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Kudo A, Yamaoka S, Tanabe M, Tanaka S. Loss of ARID1A induces a stemness gene ALDH1A1 expression with histone acetylation in the malignant subtype of cholangiocarcinoma. Carcinogenesis, 2020; 41(6):734-742.
  2. Kudo A, Akahoshi K, Ito S, Akashi T, Shimada S, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Tateishi U, Tanaka S, Tanabe M. Downregulated Pancreatic Beta Cell Genes Indicate Poor Prognosis in Patients With Pancreatic Neuroendocrine Neoplasms. Annals of Surgery, 2020; 271(4):732-739.
  3. Fujita M, Yamaguchi R, Hasegawa T, Shimada S, Arihiro K, Hayashi S, Maejima K, Nakano K, Fujimoto A, Ono A, Aikata H, Ueno M, Hayami S, Tanaka H, Miyano S, Yamaue H, Chayama K, Kakimi K, Tanaka S, Imoto S, Nakagawa H. Classification of primary liver cancer with immunosuppression mechanisms and correlation with genomic alterations. EBioMedicine, 2020; 53:102659.

2019

  1. Shimada S, Mogushi K, Akiyama Y, Furuyama T, Watanabe S, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Kudo A, Arii S, Tanabe M, Wands JR, Tanaka S. Comprehensive molecular and immunological characterization of hepatocellular carcinoma. EBioMedicine, 2019; 40:457-470.
  2. Okuno K, Akiyama Y, Shimada S, Nakagawa M, Tanioka T, Inokuchi M, Yamaoka S, Kojima K, Tanaka S. Asymmetric dimethylation at histone H3 arginine 2 by PRMT6 in gastric cancer progression. Carcinogenesis, 2019; 40(1):15-26.
  3. Fukamachi H, Kim SK, Koh J, Lee HS, Sasaki Y, Yamashita K, Nishikawaji T, Shimada S, Akiyama Y, Byeon SJ, Bae DH, Okuno K, Nakagawa M, Tanioka T, Inokuchi M, Kawachi H, Tsuchiya K, Kojima K, Tokino T, Eishi Y, Kim YS, Kim WH, Yuasa Y, Tanaka S. A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors. Journal of Experimental and Clinical Cancer Research, 2019; 38(1):127.
  4. Watanabe S, Shimada S, Akiyama Y, Ishikawa Y, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Kudo A, Yamaoka S, Tanabe M, Tanaka S. Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality. International Journal of Cancer, 2019; 145(1):192-205.
  5. Shimada S, Tanaka S. A new era for understanding genetic evolution of multistep carcinogenesis. Journal of Gastroenterology, 2019; 54(7):667-668.
  6. Asakawa M, Itoh M, Suganami T, Sakai T, Kanai S, Shirakawa I, Yuan X, Hatayama T, Shimada S, Akiyama Y, Fujiu K, Inagaki Y, Manabe I, Yamaoka S, Yamada T, Tanaka S, Ogawa Y. Upregulation of cancer-associated gene expression in activated fibroblasts in a mouse model of non-alcoholic steatohepatitis. Scientific Reports, 2019; 9(1):19601.

2018

  1. Mizuno Y, Shimada S, Akiyama Y, Watanabe S, Aida T, Ogawa K, Ono H, Mitsunori Y, Ban D, Kudo A, Arii S, Yamaoka S, Tanabe M, Tanaka S. DEPDC5 deficiency contributes to resistance to leucine starvation via p62 accumulation in hepatocellular carcinoma. Scientific Reports, 2018; 8:106.
  2. Shimada S, Akiyama Y, Mogushi K, Ishigami-Yuasa M, Kagechika H, Nagasaki H, Fukamachi H, Yuasa Y, Tanaka S. Identification of selective inhibitors for diffuse-type gastric cancer cells by screening of annotated compounds in preclinical models. British Journal of Cancer, 2018; 118(7):972-984.
  3. Chiyonobu N, Shimada S, Akiyama Y, Mogushi K, Itoh M, Akahoshi K, Matsumura S, Ogawa K, Ono H, Mitsunori Y, Ban D, Kudo A, Arii S, Suganami T, Yamaoka S, Ogawa Y, Tanabe M, Tanaka S. Fatty acid binding protein 4 (FABP4) overexpression in intratumoral hepatic stellate cells within hepatocellular carcinoma with metabolic risk factors. American Journal of Pathology, 2018; 188(5):1213-1224.
  4. Ueda H, Akiyama Y, Shimada S, Mogushi K, Serizawa M, Matsumura S, Mitsunori Y, Aihara A, Ban D, Ochiai T, Kudo A, Tanabe M, Tanaka S. Tumor suppressor functions of DAXX through histone H3.3/H3K9me3 pathway in pancreatic NETs. Endocrine-Related Cancer, 2018; 25(6):619-631.
  5. Tanaka S. Precision medicine based on surgical oncology in the era of genome-scale analysis and genome editing technology. Annals of Gastroenterological Surgery, 2018; 2(2):106-115.

2017

  1. Oba A, Shimada S, Akiyama Y, Nishikawaji T, Mogushi K, Ito H, Matsumura S, Aihara A, Mitsunori Y, Ban D, Ochiai T, Kudo A, Asahara H, Kaida A, Miura M, Tanabe M, Tanaka S. ARID2 modulates DNA damage response in human hepatocellular carcinoma cells. Journal of Hepatology, 2017; 66(5):942-951.
  2. Ohata Y, Shimada S, Akiyama Y, Mogushi K, Nakao K, Matsumura S, Aihara A, Mitsunori Y, Ban D, Ochiai T, Kudo A, Arii S, Tanabe M, Tanaka S. Acquired resistance with epigenetic alterations under long-term anti-angiogenic therapy for hepatocellular carcinoma. Molecular Cancer Therapeutics, 2017; 16(6):1155-1165.
  3. Tanaka S. Molecular analysis for therapeutic targets of pancreatic cancer. Molecular diagnosis and targeting for thoracic and gastrointestinal malignancy, 2017; ISBN:978-981-10-6469-2.

2016

  1. Ito H, Tanaka S, Akiyama Y, Shimada S, Adikrisna R, Matsumura S, Aihara A, Mitsunori Y, Ban D, Ochiai T, Kudo A, Arii S, Yamaoka S, Tanabe M. Dominant expression of DCLK1 in human pancreatic cancer stem cells accelerates tumor invasion and metastasis. PLoS ONE, 2016; 11(1):e0146564.
  2. Akiyama Y, Koda Y, Byeon SJ, Shimada S, Nishikawaji T, Sakamoto A, Chen Y, Kojima K, Kawano T, Eishi Y, Deng D, Kim WH, Zhu WG, Yuasa Y, Tanaka S. Reduced expression of SET7/9, a histone mono-methyltransferase, is associated with gastric cancer progression. Oncotarget, 2016; 7(4):3966-83.
  3. Katsuta E, Tanaka S, Mogushi K, Shimada S, Akiyama Y, Aihara A, Matsumura S, Mitsunori Y, Ban D, Ochiai T, Kudo A, Fukamachi H, Tanaka H, Nakayama K, Arii S, Tanabe M. CD73 as a therapeutic target for pancreatic neuroendocrine tumor stem cells. International Journal of Oncology, 2016; 48(2):657-69.
  4. Furuyama T, Tanaka S, Shimada S, Akiyama Y, Matsumura S, Mitsunori Y, Aihara A, Ban D, Ochiai T, Kudo A, Fukamachi H, Arii S, Kawaguchi Y, Tanabe M. Proteasome activity is required for the initiation of precancerous pancreatic lesions. Scientific Reports, 2016; 6:27044.
  5. Akahoshi K, Tanaka S, Mogushi K, Shimada S, Matsumura S, Akiyama Y, Aihara A, Mitsunori Y, Ban D, Ochiai T, Kudo A, Arii S, Tanabe M. Expression of connective tissue growth factor in the livers of non-viral hepatocellular carcinoma patients with metabolic risk factors. Journal of Gastroenterology, 2016; 51(9):910-22.
  6. Nishikawaji T, Akiyama Y, Shimada S, Kojima K, Kawano T, Eishi Y, Yuasa Y, Tanaka S. Overexpression of histone methyltransferase SETDB2 acts an oncogene in gastric cancer. Oncotarget, 2016; 7(41):67251-65
  7. Munakata K, Uemura M, Tanaka S, Kawai K, Kitahara T, Miyo M, Kano Y, Nishikawa S, Fukusumi T, Takahashi Y, Hata T, Nishimura J, Takemasa I, Mizushima T, Ikenaga M, Kato T, Murata K, Carethers JM, Yamamoto H, Doki Y, Mori M. Cancer stem-like properties in colorectal cancer cells with low proteasome activity. Clinical Cancer Research, 2016; 22(21):5277-86.
  8. Watanabe Y, Honda S, Konishi A, Satoko Arakawa S, Murohashi M, Yamaguchi H, Torii S, Tanabe M, Tanaka S, Warabi E, Shimizu S. Autophagy controls centrosome number by degrading Cep63. Nature Communications, 2016; 7:13508.
  9. Tanaka S. Molecular pathogenesis and targeted therapy of pancreatic cancer. Annals of Surgical Oncology, 2016; 23(Suppl 2):S197-205.
  10. Tanaka S. Cancer stem cells as therapeutic targets. Human Stem Cell Toxicity (Royal Society of Chemistry), 2016; 280-94.

2015

  1. Tanaka S. Cancer stem cells as therapeutic targets of hepato-biliary-pancreatic cancers. Journal of Hepato-Biliary-Pancreatic Sciences 2015; 22(7):531-7
  2. Nakao K, Tanaka S, Miura T, Sato K, Matsumura S, Aihara A, Mitsunori Y, Ban D, Ochiai T, Kudo A, Arii S, Tanabe M. Novel Aurora/vascular endothelial growth factor receptor dual kinase inhibitor as treatment for hepatocellular carcinoma. Cancer Science 2015; 106(8):1016-22.
  3. Sakamoto A, Akiyama Y, Shimada S, Zhu WG, Yuasa Y, Tanaka S. DNA Methylation in the Exon 1 Region and Complex Regulation of Twist1 Expression in Gastric Cancer Cells. PLoS ONE 2015; 10(12):e0145630.
  4. Watanabe Y, Yamamoto H, Oikawa R, Toyota M, Yamamoto M, Kokudo N, Tanaka S, Arii S, Yotsuyanagi H, Koike K, Itoh F. DNA methylation at hepatitis B viral integrants is associated with methylation at flanking human genomic sequences. Genome Research 2015; 25(3):328-37.
  5. Okajima C, Arii S, Tanaka S, Matsumura S, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Tanabe M. Prognostic role of Child-Pugh score 5 and 6 in hepatocellular carcinoma patients who underwent curative hepatic resection. American Journal of Surgery 2015; 209(1):199-205.
  6. Matsunaga H, Tanaka S, Aihara A, Ogawa K, Matsumura S, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Arii S, Tanabe M. A novel therapeutic combination targeting sequentially Aurora B and Bcl-xL in hepatocellular carcinoma. Annals of Surgical Oncology 2015; 22(9):3079-86.
  7. Miura T, Ban D, Tanaka S, Mogushi K, Kudo A, Matsumura S, Mitsunori Y, Ochiai T, Tanaka H, Tanabe M. Distinct clinicopathological phenotype of hepatocellular carcinoma with EOB-MRI hyperintensity: association with gene expression signature. American Journal of Surgery 2015; 210(3):561-9.

2014

  1. Uno M, Saitoh Y, Mochida K, Tsuruyama E, Kiyono T, Imoto I, Inazawa J, Yuasa Y, Kubota T, Yamaoka S. NF-κB inducing kinase, a central signaling component of the non-canonical pathway of NF-κB, contributes to ovarian cancer progression. PLoS ONE 2014; 9(2):e88347.
  2. Tsuchida R, Osawa T, Wang F, Nishii R, Das B, Tsuchida S, Muramatsu M, Takahashi T, Inoue T, Wada Y, Minami T, Yuasa Y, Shibuya M. BMP4/Thrombospondin-1 loop paracrinically inhibits tumor angiogenesis and suppresses the growth of solid tumors. Oncogene 2014; 33(29):3803-11.
  3. Chen L, Fu L, Kong X, Xu J, Wang Z, Ma X, Akiyama Y, Chen Y, Fang J. Jumonji domain-containing protein 2B silencing induces DNA damage response via STAT3 pathway in colorectal cancer. British Journal of Cancer 2014; 110(4):1014-26.
  4. Ogawa K, Tanaka S, Matsumura S, Murakata A, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Tanabe M, Arii S. EpCAM-targeted therapy for human hepatocellular carcinoma. Annals of Surgical Oncology 2014; 21(4):1314-22.
  5. Katsuta E, Tanaka S, Mogushi K, Matsumura S, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Tanaka H, Tanabe M, Arii S. Age-related clinicopathological and molecular features of patients received curative hepatectomy for hepatocellular carcinoma. American Journal of Surgery 2014; 208(3):450-6.

2013

  1. Fukamachi H, Kato S, Asashima M, Ichinose M, Yuasa Y. Activin A regulates growth of gastro-intestinal epithelial cells by mediating epithelial-mesenchymal interaction. Development Growth and Differentiation 2013; 55(9):786-791.
  2. Fukamachi H, Seol HS, Shimada S, Funasaka C, Baba K, Kim JH, Park YS, Kim MJ, Kato K, Inokuchi M, Kawachi H, Yook JH, Eishi Y, Kojima K, Kim WH, Jang SJ, Yuasa Y. CD49fhigh cells retain sphere-forming and tumor-initiating activities in human gastric tumors. PLoS One 2013; 8(8):e72438.
  3. Hashimoto Y, Akiyama Y, Yuasa Y. Multiple-to-multiple relationships between microRNAs and target genes in gastric cancer. PLoS One 2013; 8(5):e62589.
  4. Osawa T, Tsuchida R, Muramatsu M, Shimamura T, Wang F, Suehiro J, Kanki Y, Wada Y, Yuasa Y, Aburatani H, Miyano S, Minami T, Kodama T, Shibuya M. Inhibition of histone demethylase JMJD1A improves anti-angiogenic therapy and reduces tumor associated macrophages. Cancer Research 2013; 73(10):3019-3028.
  5. Rotkrua P, Shimada S, Mogushi, K, Akiyama Y, Tanaka H, Yuasa Y. Circulating microRNAs as biomarkers for early detection of diffuse-type gastric cancer using a mouse model. British Journal of Cancer 2013; 108(4):932-940.
  6. Sato K, Tanaka S, Mitsunori Y, Mogushi K, Yasen M, Aihara A, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Tanaka H, Arii S. Contrast-enhanced intraoperative ultrasonography for vascular imaging of hepatocellular carcinoma; clinical and biological significance. Hepatology, 2013;57(4):1436-1447.
  7. Muramatsu S, Tanaka S, Mogushi K, Adikrisna R, Aihara A, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Tanaka H, Nakayama K, Tanaka H, Yamaoka S, Arii S. Visualization of stem cell features in human hepatocellular carcinoma enlightened in vivo significance of tumor-host interaction and clinical implication. Hepatology, 2013 Jul;58(1):218-228.
  8. Sakai S, Tanaka S, Kawakami K, Arii S. Cell-enclosing microparticles and microcapsules production using a water-immiscible fluid under laminar flow and application to cell therapy. in Bioencapsulation of Living Cells for Diverse Medical Applications, ed. Brandtner EM, Dangerfield JA. Pp153-177, (Bentham Science Publishers), 2013 
  9. Compositions and methods for detection and treatment of hepatocellular carcinoma
    Shinji Tanaka & Glen MacDonald (04/12/2013), Viventia Bio Inc.

2012

  1. Shimada S, Mimata A, Sekine M, Mogushi K, Akiyama Y, Fukamachi H, Jonkers J, Tanaka H, Eishi Y, Yuasa Y. Synergistic tumour suppressor activity of E-cadherin and p53 in a conditional mouse model for metastatic diffuse-type gastric cancer. Gut 2012:61:344-353.
  2. Yuasa Y, Nagasaki H, Oze I, Akiyama Y, Yoshida S, Shitara K, Ito S, Hosono S, Watanabe M, Ito H, Tanaka H, Kang DH, Pan K-F, You W-C, Matsuo K. IGF2 hypomethylation of blood leukocyte DNA is associated with gastric cancer risk. Int. J. Cancer 2012:131:2596-2603.
  3. Song M-Y, Pan K-F, Su H-J, Zhang L, Ma J-L, Li J-Y, Yuasa Y, KangDH, Kim YS, You W-C. Identification of serum microRNAs as novel non-invasive biomarkers for early detection of gastric cancer. PLoS One 2012:7:e33608.
  4. Li L, Choi JY, Lee KM, Sung H, Park SK, Oze I, Pan KF, You WC, Chen YX, Fang JY, Matsuo K, Kim WH, Yuasa Y, Kang D. DNA methylation in peripheral blood: a potential biomarker for cancer molecular epidemiology. J. Epidemiol. 2012:22:384-394.
  5. Voon D. C., Wang, H., Koo, J. K., Nguyen, T. A., Hor, Y. T., Chu, Y. S., Ito, K., Fukamachi, H., Chan, S. L., Thiery, J. P., Ito, Y. (2012) Runx3 protects gastric epithelial cells against epithelial-mesenchymal transition-induced cellular plasticity and tumorigenicity. Stem Cells 2012:30:2088-2099.
  6. Tsuchiya, Y., Saito, Y., Taniuchi, S., Sakuma, A., Maekawa, T., Fukamachi, H., Takeuchi, S., Takahashi, S. (2012) Runx3 expression and its roles in mouse endometrial cells. J. Reprod. Develop. 2012:58:592-598.
  7. Tanaka S, Arii S. Molecular targeted therapies in hepatocellular carcinoma. Seminars in Oncology, 2012:39(6):486-92.
  8. Adikrisna R, Tanaka S, Muramatsu S, Aihara A, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Yamaoka S, Arii S. Identification of pancreatic cancer stem cells and selective toxicity of chemotherapeutic agents. Gastroenterology, 2012;143(1):234-245.
  9. Matsumura S, Imoto I, Kozaki K, Matsui T, Muramatsu T, Furuta M, Tanaka S, Sakamoto M, Arii S, Inazawa J. Integrative array-based approach identifies MZB1 as a frequently methylated putative tumor-suppressor in hepatocellular carcinoma. Clin Cancer Res, 2012 Jul 1;18(13):3541-3551.
  10. Sakai S, Inamoto K, Liu Y, Tanaka S, Arii S, Taya M. Multicellular tumor spheroid formation in duplex microcapsules for analysis of chemosensitivity. Cancer Science, Mar;103(3):549-54, 2012.

2011

  1. Otsubo T, Akiyama Y, Hashimoto Y, Shimada S, Goto K, Yuasa Y: MicroRNA-126 inhibits SOX2 expression and contributes to gastric carcinogenesis. PLoS One 2011:6:e16617.
  2. Mimata A, Fukamachi H, Eishi Y, Yuasa Y: Loss of E-cadherin in mouse gastric epithelial cells induces signet ring-like cells, a possible precursor lesion of diffuse gastric cancer. Cancer Sci. 2011:102:942-950.
  3. Fukamachi H, Shimada S, Ito K, Ito Y, Yuasa Y. CD133 is a marker of gland-forming cells in gastric tumors and Sox17 is involved in its regulation. Cancer Sci. 2011:102:1313-1321.
  4. Rotkrua P, Akiyama Y, Hashimoto Y, Otsubo T, Yuasa Y: MiR-9 down-regulates CDX2 expression in gastric cancer cells. Int.J.Cancer 2011:129:2611-2620.
  5. Wang F, Osawa T, Tsuchida R, Yuasa Y, Shibuya M. Downregulation of receptor for activated C-kinase 1 (RACK1) suppresses tumor growth by inhibiting tumor cell proliferation and tumor-associated angiogenesis. Cancer Sci. 2011:102:2007-2013
  6. Ito K, Chuang L. S. H, Ito T, Chang TL, Fukamachi H, Salto–Tellez M, Ito Y. Loss of Runx3 is a key event in inducing precancerous state of the stomach. Gastroenterology 2011:140:1536-1546.
  7. Dhondt J, Peeraer E, Verheyen A, Nuydens R, Buysschaert I, Poesen K, Van Geyte K, Beerens M, Shibuya M, Haigh JJ, Meert T, Carmeliet P, Lambrechts D. Neuronal FLT1 receptor and its selective ligand VEGF-B protect against retrograde degeneration of sensory neurons. FASEB J 2011:25:1461-1473.
  8. Kato T, Ito Y, Hosono K, Suzsuki T, Tamaki H, Minamino T, Kato S, Sakagami H, Shibuya M, Majima M. Vascular endothelial growth factor receptor-1 signaling promotes liver repair through restoration of liver microvasculature after acetaminophen hepatotoxicity. Toxicol Sci. 2011:120:218-229.
  9. Wang F, Yamauchi M, Muramatsu M, Osawa T, Tsuchida R, Shibuya M. RACK1 regulates VEGF/Flt1-mediated cell migration via activation of a PI3K/Akt pathway. J Biol Chem. 2011:286:9097-9106.
  10. Osawa T, Tsuchida R, Muramatsu M, Yuasa Y, Shibuya M. Human glioblastoma cells exposed to long-term hypoxia and nutrient starvation stimulated induction of secondary T cell leukemia in mice. Blood Cancer J, 2011:1, e6.
  11. Lu Y, Xiong Y, Huo Y, Han J, Yang X, Zhang R, Zhu DS, Klein-Heßling S, Li J, Zhang X, Han X, Li Y, Shen B, He Y, Shibuya M, Feng GS, Luo J. Grb-2-associated binder 1 (Gab1) regulates postnatal ischemic and VEGF-induced angiogenesis through the protein kinase A-endothelial NOS pathway. Proc Natl Acad Sci U S A. 2011:108:2957-2962.
  12. Kubota Y, Takubo K, Hirashima M, Nagoshi N, Kishi K, Okuno Y, Nakamura-Ishizu A, Sano K, Murakami M, Ema M, Omatsu Y, Takahashi S, Nagasawa T, Shibuya M, Okano H, Suda T. Isolation and function of tissue resident vascular precursors marked by myelin protein zero. J Exp Med. 2011:208:949-960.
  13. Brave SR, Ratcliffe K, Wilson Z, James N, Ashton SE, Wainwright A, Kendrew J, Dudley P, Broadbent N, Sproat G, Taylor S, Barnes C, Silva JC, Farnsworth CL, Hennequin L, Ogilvie DJ, Jürgensmeier JM, Shibuya M, Wedge SR, Barry ST. Assessing the Activity of Cediranib, a VEGFR-2/-3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR-family. Mol Cancer Ther. 2011:10:861-873.
  14. Laurent J, Faes-Van't Hull E, Touvrey C, Kuonen F, Lan Q, Lorusso G, Doucey MA, Ciarloni L, Imaizumi N, Alghisi GC, Fagiani E, Zaman K, Stupp R, Shibuya M, Delaloye JF, Christofori G, Ruegg C. Proangiogenic programming of CD11b+ myelomonocytes in breast cancer by PlGF during hematopoietic progenitors differentiation. Cancer Res. 2011:71:3781-3791.
  15. Yao J, Wu X, Zhuang G, Kasman IM, Vogt T, Phan V, Shibuya M, Ferrara N, Bais C. Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy. Proc Natl Acad Sci U S A. 2011:108:11590-11595.
  16. Wang F, Osawa T, Tsuchida R, Yuasa Y, Shibuya M. Down-regulation of RACK1 suppresses tumor growth by inhibiting tumor cell proliferation and tumor-associated angiogenesis. Cancer Sci. 2011:102:2007-2013.
  17. Bhardwaj S, Roy H, Babu M, Shibuya M, Yla-Herttuala S. Adventitial gene transfer of VEGFR-2 specific VEGF-E chimera induces MCP-1 expression in vascular smooth muscle cells and enhances neointimal formation. Atherosclerosis. 2011:219: 84-91.
  18. Han J, Lee JE, Jin J, Lim JS, Oh N, Kim K, Chang SI, Shibuya M, Kim H, Koh GY. The spatiotemporal development of adipose tissue. Development. 2011:138:5027-5037.
  19. Osawa T, Muramatsu M, Wang F, Tsuchida R, Kodama T, Minami T, Shibuya M. Increased expression of histone demethylase JHDM1D under nutrient starvation suppresses tumor growth via downregulating angiogenesis. Proc Natl Acad Sci U S A. 2011:108:20725-20729.
  20. Tanaka S, Mogushi K, Yasen M, Ban D, Noguchi N, Kudo A, Nakamura N, Tanaka H, Yamamoto M, Kokudo N, Takayama T, Kawasaki S, Sakamoto M, Arii S. Oxidative stress pathways in non-cancerous human liver tissue to predict hepatocellular carcinoma recurrence; a prospective multi-center study. Hepatology, 54(4):1273-1281, 2011.
  21. Tanaka S, Arii S. Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies. Journal of Gastroenterology, Mar;46(3):289-96, 2011.
  22. Murakata A, Tanaka S, Mogushi K, Yasen M, Noguchi N, Irie T, Kudo A, Nakamura N, Tanaka H, Arii S. Gene expression signature of the gross morphology in hepatocellular carcinoma. Annals of Surgery, 253(1): 94-100, 2011.
  23. Yoshitake Y, Tanaka S, Mogushi K, Aihara A, Murakata A, Matsumura S, Mitsunori Y, Yasen M, Ban D, Noguchi N, Irie T, Kudo A, Nakamura N, Tanaka H, Arii S. Importin-alpha1 as a novel prognostic target for hepatocellular carcinoma. Ann Surg Oncol, Jul; 18(7):2093-103, 2011.

2010

  1. Wada R, Akiyama Y, Hashimoto Y, Fukamachi H, Yuasa Y: miR-212 is down-regulated and suppresses methyl-CpG-binding protein MeCP2 in human gastric cancer. Int.J.Cancer.127:1106-1114.
  2. Hashimoto Y, Akiyama Y, Otsubo T, Shimada S, Yuasa Y: Involvement of epigenetically silenced microRNA-181c in gastric carcinogenesis. Carcinogenesis.31:774-784.
  3. Wen XZ, Akiyama Y, Pan KF, Liu ZJ, Lu ZM, Zhou J, Gu LK, Dong CX, Zhu BD, Ji JF, You WC, Deng DJ: Methylation of GATA-4 and GATA-5 and development of sporadic gastric carcinomas. World J. Gastroenterology, 2010:16:1201-1208.
  4. Chang TL, Ito K, Ko TK, Liu Q, Salto-Tellez M, Yeoh KG, Fukamachi H, Ito Y: Claudin-1 has tumor suppressive activity and is a direct target of RUNX3 in gastric epithelial cells. Gastroenterology, 2010:138:255-265.
  5. Tanaka S, Mogushi K, Yasen M, Noguchi N, Kudo A, Nakamura N, Ito K, Miki Y, Inazawa J, Tanaka H, Arii S. Gene expression phenotypes for vascular invasiveness of hepatocellular carcinomas. Surgery, 147(3):405-414, 2010.
  6. Tanaka S, Arii S. Novel molecular-targeted therapy for hepatocellular carcinoma. Journal of Hepato-Biliary Pancreatic Surgery, 7(4):413-9, 2010.
  7. Tanaka S, Arii S. Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science. International Journal of Clinical Oncology, 15(3):235-41, 2010.
  8. Aihara A, Tanaka S, Yasen M, Matsumura S, Mitsunori Y, Murakata A, Noguchi N, Kudo A, Nakamura N, Ito K, Arii S. The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. Journal of Hepatology, 52(1):63-71, 2010.
  9. Arii S, Tanaka S, Mitsunori Y, Nakamura N, Kudo A, Noguchi N, Irie T. Surgical strategies for hepatocellular carcinoma with special reference to anatomical hepatic resection and intraoperative contrast-enhanced ultrasonography. Oncology, 78 Suppl 1:125-30, 2010.
  10. Yuasa Y: Epigenetics in molecular epidemiology of cancer: a new scope. Adv Genet. 2010:71:211-235.

2009

  1. Yuasa Y, Nagasaki H, Akiyama Y, Hashimoto Y, Takizawa T, Kojima K, Kawano T, Sugihara K, Imai K, and Nakachi K: DNA methylation status is inversely correlated with green tea intake and physical activity in gastric cancer patients. Int. J. Cancer 2009:124:2677-2682.
  2. Hellebrekers DMEI, Lentjes, MHFM, van den Bosch SM, Wouters AD, Daenen K, Melotte V, Smits KM, Partouns-Hendriks IEJM, Akiyama Y, Yuasa Y, Sanduleanu S, Khalid-de Bakker C, Jonkers D, Weijenberg MP, Louwagie J, van Criekinge W, Carvalho B, Meijer GA, Baylin SB, Herman JG, de Bru?ne AP & van Engeland M: GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer. Clinical Cancer Res., 2009:15:3990-3997.
  3. Komi Y, Suzuki Y, Shimamura M, Kajimoto S, Nakajo S, Masuda M, Shibuya M, Itabe H, Shimokado K, Oettgen P, Nakaya K, Kojima S. Mechanism of Inhibition of Tumor Angiogenesis by beta-Hydroxyisovalerylshikonin. Cancer Sci. 100:269-277, 2009.
  4. Osawa T, Muramatsu M, Watanabe M, Shibuya M. Hypoxia and Low Nutrition Double Stress Induces Aggressiveness in a Murine Model of Melanoma. Cancer Sci. 100:844-851, 2009.
  5. Kubota Y, Takubo K, Shimizu T, Ohno H, Kishi K, Shibuya M, Saya H, Suda T. M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J Exp Med. 206:1089-102, 2009
  6. Wittko IM, Sch?nzer A, Kuzmichev A, Schneider FT, Shibuya M, Raab S, Plate KH. VEGFR-1 regulates adult olfactory bulb neurogenesis and migration of neural progenitors in the rostral migratory stream in vivo. J Neurosci. 29: 8704-8714, 2009.
  7. Imai N, Miwa H, Shikami M, Suganuma K, Gotoh M, Hiramatsu A, Wakabayashi M, Watarai M, Hanamura I, Imamura A, Mihara H, Shitara K, Shibuya M, Nitta M. Growth inhibition of AML cells with specific chromosome abnormalities by monoclonal antibodies to receptors for vascular endothelial growth factor. Leukemia Res. 33: 1650-1657, 2009.
  8. Xiong Y, Huo Y, Chen C, Zeng H, Lu X, Wei C, Ruan C, Zhang X, Hu Z, Shibuya M, Luo J. VEGF Receptor-2 Y1175 signaling controls VEGF-induced vWF release from endothelial cells via PLCgamma1- and PKA-dependent pathways. J Biol Chem. 284: 23217-2324, 2009.
  9. Suzuki H, Ohkuchi A, Matsubara S, Takei Y, Murakami M, Shibuya M, Suzuki M, Sato Y. Effect of recombinant placental growth factor 2 on hypertension induced by full-length mouse soluble fms-like tyrosine kinase 1 adenoviral vector in pregnant mice. Hypertension. 54:1129-1135, 2009.
  10. Tanaka S, Arii S. Molecularly targeted therapy for hepatocellular carcinoma. Cancer Science, 100(1):1-8, 2009.
  11. Tanaka S, Mogushi K, Yasen M, Noguchi N, Kudo A, Kurokawa T, Nakamura N, Inazawa J, Tanaka H, Arii S. Surgical contribution to recurrence-free survival in patients with macrovascular invasion-negative hepatocellular carcinoma. Journal of the American College of Surgeons, 208(3):368–374, 2009.
  12. Tanaka S, Shimada M, Shirabe K, Taketomi A, Maehara Si, Tsujita E, Ito S, Kitagawa D, Maehara Y. Surgical radiofrequency ablation for treatment of hepatocellular carcinoma: an endoscopic or open approach. Hepatogastroenterology, Jul-Aug;56(93):1169-73, 2009.
  13. Yasen M, Mizushima H, Mogushi K, Obulhasim G, Miyaguchi K, Inoue K, Nakahara I, Ohta T, Aihara A, Tanaka S, Arii S, Tanaka H. Expression of Aurora B and their alternative variant forms in hepatocellular carcinoma and the adjacent tissue. Cancer Science, 100(3):368-74, 2009.
  14. Sakai S, Hashimoto I, Tanaka S, Salmons B, Kawakami K. Small agarose microcapsules with cell-enclosing hollow core for cell therapy: Transplantation of ifosfamide-activating cells to the mice with pre-established subcutaneous tumor. Cell Transplantation, 18(8):933-9, 2009.

2008

  1. Jin S-H, Akiyama Y, Fukamachi H, Yanagihara K, Akashi T, Yuasa Y: IQGAP2 inactivation through aberrant promoter methylation and promotion of invasion in gastric cancer cells. Int. J. Cancer, 2008:122:1040-1046.
  2. Otsubo T, Akiyama Y, Yanagihara K, Yuasa Y: SOX2 is frequently down-regulated in gastric cancers and inhibits  cell growth through cell cycle arrest and apoptosis. Brit. J. Cancer 2008:98:824-831.
  3. Wanajo A , Sasaki A , Nagasaki H, Shimada S, Otsubo T, Owaki S, Shimizu Y, Eishi Y, Kojima K, Nakajima Y, Kawano T, Yuasa Y, Akiyama Y: Methylation of the calcium channel-related gene, CACNA2D3, is frequent and a poor prognostic factor in gastric cancer. Gastroenterology, 2008:135:80-590.
  4. Fukamachi H, Mimata A, Tanaka I, Ito K, Ito Y, Yuasa, Y: Differentiation in vitro of Runx3-/-p53-/- gastric epithelial cells into intestinal type cells. Cancer Sci. 2008:99:671-676.
  5. Kurakata H, Oka M, Matsubara Y, Niwa T, Utsunomiya H, Fujishiro M, Miki K, Fukamachi H, Kubota S, Ichinose M: Developmentally regulated expression of matrix metalloproteinases during fetal rat colon morphogenesis. Develop Growth Differ., 2008:50: 41-48.
  6. Sakuma A, Fukamachi H, Ito K, Ito Y, Takeuchi S, Takahashi S: Loss of Runx3 affects ovulation and estrogen-induced endometrial cell proliferation in female mice. Mol Reprod Develop., 2008:75:1653-1661.
  7. Ito K, Lim A. C.-B, Salto-Tellez M, Motoda L, Osato M, Chuang L. S. H, Lee C. W. L, Voon D. C.-C, Koo J. K. W, Wang H, Fukamachi H, Ito Y: RUNX3 attenuates β-catenin/T cell factors in intestinal tumorigenesis. Cancer Cell, 2008:14: 226-237.
  8. Hiratsuka S, Watanabe A, Sakurai Y, Akashi-Takamura S, Ishibashi S, Miyake K, Shibuya M, Akira S, Aburatani H, Maru Y. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol. 10:1349-1355, 2008.
  9. Poesen K, Lambrechts D, Van Damme P, Dhondt J, Bender F, Frank N, Bogaert E, Claes B, Heylen L, Verheyen A, Raes K, Tjwa M, Eriksson U, Shibuya M, Nuydens R, Van Den Bosch L, Meert T, D'Hooge R, Sendtner M, Robberecht W, Carmeliet P. Novel Role for VEGF-Receptor-1 and its Ligand VEGF-B in Motor Neuron Degeneration. J Neurosci 28: 10451-10459, 2008.
  10. Nishi JI, Minamino T, Miyauchi H, Nojima A, Tateno K, Okada S, Orimo M, Moriya J, Fong GH, Sunagawa K, Shibuya M, Komuro I. Vascular Endothelial Growth Factor Receptor-1 Regulates Postnatal Angiogenesis Through Inhibition of the Excessive Activation of Akt. Circulation Res 103: 261-268, 2008.
  11. Kami J, Muranaka K, Yanagi Y, Obata R, Tamaki Y, Shibuya M. Inhibition of choroidal neovascularization by blocking vascular endothelial growth factor receptor tyrosine kinase. Jpn J Ophthalmol 52: 91-98, 2008.
  12. Kerber M, Reiss Y, Wickersheim A, Jugold M, Kiessling F, Heil M, Tchaikovski V, Waltenberger J, Shibuya M, Plate KH, Machein MR. Flt-1 signaling in macrophages promotes glioma growth in vivo. Cancer Res 68: 7342-7351, 2008.
  13. Tammela T, Zarkada G, Wallgard E, Murtomaki A, Suchting S, Wirzenius M, Waltari M, Hellstrom M, Schomber T, Peltonen R, Freitas C, Duarte A, Isoniemi H, Laakkonen P, Christofori G, Yla-Herttuala S, Shibuya M, Pytowski B, Eichmann A, Betsholtz C, Alitalo K. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 54: 656-660, 2008.
  14. Fukuhara S, Sako K, Minami T, Noda K, Kim HZ, Kodama T, Shibuya M, Takakura N, Koh GY, Mochizuki N. Differential function of Tie2 at cell-cell contacts and cell-substratum contacts regulated by angiopoietin-1. Nat Cell Biol 10: 513-526, 2008.
  15. Endo Y, Sugiyama A, Li SA, Ohmori K, Ohata H, Yoshida Y, Shibuya M, Takei K, Enari M, Taya Y. Regulation of clathrin-mediated endocytosis by p53. Genes Cells 13: 375-386, 2008.
  16. Tsuchida R, Das B, Yeger H, Koren G, Shibuya M, Thorner PS, Baruchel S, Malkin D. Cisplatin treatment increases survival and expansion of a highly tumorigenic side-population fraction by upregulating VEGF/Flt1 autocrine signaling. Oncogene 27: 3923-3934, 2008.
  17. Murakami, M. Zheng Y, Hirashima M, Suda T, Morita Y, Ooehara J, Ema H, Fong GH, Shibuya M. VEGFR1 Tyrosine Kinase Signaling Promotes Lymphangiogenesis as Well as Angiogenesis Indirectly via Macrophage Recruitment. Arterioscler Thromb Vasc Biol 28: 658-664, 2008.
  18. Taguchi, E., Nakamura K, Miura T, Shibuya M, Isoe T. Anti-tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model. Cancer Sci 99: 623-630, 2008.
  19. Tanaka S, Arii S, Yasen M, Mogusi K, Su N-T, Zhao C, Imoto I, Eishi Y, Inazawa J, Miki Y, Tanaka H. Aurora kinase B is a predictive factor for aggressive recurrence of hepatocellular carcinoma after curative hepatectomy. British Journal of Surgery, 95(5):611-9, 2008
  20. Tanaka S, Taira K, Kudo A, Nakamura N, Ito K, Arii S. Anterior approach for left-sided hepatic resection. Hepatogastroenterology, 55 (86-87); 1760-3, 2008.
  21. Yuasa Y: Frontiers in epigenetics medicine: foreword: Miniseries collected from a symposium organized by the Study Group on Epigenetics Medicine held at the 77th Annual Meeting of the Japanese Society for Hygiene. Environ. Health Prev. Med., 2008:13:2.
  22. Murakami M, Shibuya M. Involvement of vascular endothelial growth factor receptor-1 in rheumatoid arthritis. Inflammation and Regeneration, 28: 78-85, 2008.
  23. Shibuya M. Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep 41: 278-286, 2008.

2007

  1. Tani Y, Akiyama Y, Fukamachi H, Yanagihara K, Yuasa Y: Transcription factor SOX2 up-regulates stomach-specific pepsinogen A gene expression. J. Cancer Res. Clin. Oncol. 133: 263-269, 2007.
  2. Jinawath A, Akiyama Y, Sripa B, Yuasa Y: Dual blockade of the Hedgehog and ERK1/2 pathways coordinately decreases proliferation and survival of cholangiocarcinoma cells. J. Cancer Res. Clin. Oncol. 133: 271-278, 2007.
  3. Satoh Y, Ohkawa R, Nakamura K, Higashi K, Kaneko M, Yokota H, Aoki J, Arai H, Yuasa Y, Yatomi Y: Lysophosphatidic acid protection against apoptosis in the human pre-B-cell line Nalm-6. Eur. J. Haemat. 78:510-517, 2007.
  4. Makita N, Sato J, Rondard P, Fukamachi H, Yuasa Y, Aldred MA, Hashimoto M, Fujita T, Iiri T: Human Gs mutant causes pseudohypoparathyroidism type Ia/neonatal diarrhea, a potential cell-specific role of the palmitoylation cycle. Proc. Natl. Acad. Sci. U.S.A. 2007:104:17424-17429.
  5. Taniwaki K, Fukamachi H, Komori K, Ohtake Y, Nonaka T, Sakamoto T, Shiomi T, Okada Y, Itoh T, Itohara S, Seiki M, Yana I: Stroma-derived matrix metalloproteinase (MMP)-2 promotes membrane type 1-MMP-dependent tumor growth in mice. Cancer Res., 67:4311-4319, 2007.
  6. Inoue N, Kondo T, Kobayashi K, Aoki M, Numaguchi Y, Shibuya M, Murohara T: Therapeutic Angiogenesis Using Novel Vascular Endothelial Growth Factor-E/Human Placental Growth Factor Chimera Genes. Arterioscler Thromb Vasc Biol., 27:99-105, 2007.
  7. Shinoda G, Umeda K, Heike T, Arai M, Niwa A, Ma F, Suemori H, Luo HY, Chui DH, Torii R, Shibuya M, Nakatsuji N, Nakahata T: {alpha}4-integrin+ endothelium derived from primate embryonic stem cells generates both primitive and definitive hematopoietic cells. Blood. 109:2406-2415, 2007.
  8. Zheng Y, Watanabe M, Kuraishi T, Hattori S, Kai C, Shibuya M: Chimeric VEGF-ENZ7/PlGF Specifically Binding to VEGFR-2 Accelerates Skin Wound Healing via Enhancement of Neovascularization. Arterioscler, Thromb, Vasc. Biol., 27:503-511, 2007.
  9. Wirzenius M, Tammela T, Uutelaff M, He Y, Odorisio T, Sambruno G, Nagy JA, Dvorak HF, Yla-Herttuala S, Shibuya M, Alitalo K: Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting. J. Exp. Med. 204:1431-1340, 2007.
  10. Nagano M, Yamashita T, Hamada H, Ohneda K, Kimura K, Nakagawa T, Shibuya M, Yoshikawa H, Ohneda O: Identification of functional endothelial progenitor cells suitable for the treatment of ischemic tissue using human umbilical cord blood. Blood. 110:151-160, 2007.
  11. Yamauchi M, Imajoh-Ohmi S, Shibuya M: A novel anti-angiogenic pathway of thrombospondin-1 mediated by suppression of the cell cycle. Cancer Science 98:1491-1497, 2007.
  12. Kunizaki M, Hamamoto R, Silva FP, Yamaguchi K, Nagayasu T, Shibuya M, Nakamura Y, Furukawa Y.The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3. Cancer Res., 67:10759-1065, 2007.
  13. Usui R, Shibuya M, Ishibashi S, Maru Y: Ligand-independent activation of vascular endothelial growth factor receptor 1 by low-density lipoprotein. EMBO Rep. 8:1155-1161, 2007.
  14. Tanaka S, Noguchi N, Ochiai T, Kudo A, Nakamura N, Ito K, Kawamura T, Teramoto K, Arii S. Outcomes and recurrence of initially resection of hepatocellular carcinoma meeting Milan criteria: Rationale for partial hepatectomy as first strategy. Journal of the American College of Surgeons, 204(1):1-6, 2007.
  15. Tanaka S, Kawamura T, Nakamura N, Teramoto K, Arii S. Mucinous cystadenocarcinoma of the pancreas developing during hormone replacement therapy. Digestive Diseases and Sciences, 52(5):1326-8, 2007.
  16. Tanaka S. Molecular targeting therapy against a novel metastasis regulator of pancreatic cancer. Recent Advances and Research Updates 8 (1): 230-239, 2007
  17. Yanagita T, Kubota S, Kwaki H, Kawata K, Kondo S, Takano-Yamamoto T, Tanaka S, Takagawa M. Expression and physiological role of CCN4/Wnt-induced secreted protein 1 mRNA splicing variants in chondrocytes. FEBS Journal, 274(7):1655-6, 2007
  18. Ito S, Taketomi A, Tanaka S, Harimoto N, Aishima Si, Maeda T, Shirabe K, Shimada M, Maehara Y. Clinical and biological significance of growth factor receptor bound protein 7 (Grb7) in hepatocellular carcinoma. Molecular Cancer Research, 5(7):667-73, 2007

2006

  1. Wen X-Z, Akiyama Y, Baylin SB, Yuasa Y: Frequent epigenetic silencing of the bone morphogenetic protein 2 gene through methylation in gastric carcinomas. Oncogene 2006:25:2666-2673.
  2. Wakana K, Akiyama Y, Aso T, Yuasa Y: Involvement of GATA-4/-5 transcription factors in ovarian carcinogenesis. Cancer Letters 2006:241:281-288.
  3. Sekine A, Akiyama Y, Yanagihara K, Yuasa Y: Hath1 up-regulates gastric mucin genes in gastric cells. Biochem. Biophys. Res. Commun. 2006:344:1166-1171.
  4. Jinawath A, Akiyama Y, Yuasa Y, Pairojkul C: Expression of phosphorylated ERK1/2 and homeodomain protein CDX2 in cholangiocarcinoma. J. Cancer Res. Clin. Oncol. 2006:132:805-810.
  5. Tsuruzoe S, Ishihara K, Uchimura Y, Watanabe S, Sekita Y, Aoto T, Saitoh H, Yuasa Y, Niwa H, Kawasuji M, Baba H, Nakao M: Inhibition of DNA binding of Sox2 by the SUMO conjugation. Biochem. Biophys. Res. Commun. 2006:351:920-926.
  6. Guo M, House MG, Akiyama Y, Qi Y, Capagna DC, Harmon J, Baylin SB, Brock MV, Herman JG: Hypermethylation of the GATA gene family in esophageal cancer. Int. J. Cancer 2006:119:2078-2083.
  7. Takano-Maruyama M, Hase K, Fukamachi H, Kato Y, Koseki H, Ohno H: Foxl1-deficient mice exhibit aberrant epithelial cell positioning due to dysregulated EphB/EphrinB expression in the small intestine. Amer J Physiol Gastrointest Liver Physiol 2006:291:G163-G170.
  8. Yano T, Ito K, Fukamachi H, Chi X-Z, Wee H-J, Inoue K, Ida H, Bouillet P, Strasser A, Bae S-C, Ito Y: The RUNX3 tumor suppressor upregulates Bim in gastric epithelial cells undergoing transforming growth factor ?-induced apoptosis. Mol Cell Biol 2006:26:4474-4488.
  9. Tanaka S, Wands JR, Arii S. Induction of Angiopoietin-2 gene expression by COX-2: A novel role for COX-2 inhibitors during hepatocarcinogenesis. Journal of Hepatology, 44(1):233-5, 2006
  10. Tanaka S, Pero SC, Taguchi K, Shimada M, Mori M, Krag DN, Arii S. Specific peptide ligand for Grb7 signal transduction protein and pancreatic cancer metastasis. Journal of the National Cancer Institute, 98(7);491-8, 2006
  11. Tanaka S, Arii S. Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma. International Journal of Clinical Oncology, 11(2):82-9, 2006.

2005

  1. Yuasa Y, Nagasaki H, Akiyama Y, Sakai H, Nakajima T, Ohkura Y, Takizawa T, Koike M, Tani M, Iwai T, Sugihara K, Imai K, Nakachi K: Relationship between CDX2 gene methylation and dietary factors in gastric cancer patients. Carcinogenesis 2005:26:193-200.
  2. Jinawath A, Miyake S, Yanagisawa Y, Akiyama Y, Yuasa Y: Transcriptional regulation of the human DNA methyltransferase 3A and 3B genes by Sp3 and Sp1 zinc finger proteins. Biochemical J. 2005:385:557-564.
  3. Wu XS, Akiyama Y, Igari T, Kawamura T, Hiranuma S, Shibata T, Tsuruta K, Koike M, Arii S, Yuasa Y: Expression of homeodomain protein CDX2 in gallbladder carcinomas. J. Cancer Res. Clin. Oncol., 2005:131:271-278.
  4. Maekawa M, Yamamoto T, Tanoue T, Yuasa Y, Chisaka O, Nishida E: Requirement of the MAP kinase signaling pathways for mouse preimplantation development. Development 2005:132:1773-1783.
  5. Sasajima Y, Tanaka H, Miyake S, Yuasa Y: A novel EID family member, EID-3, forms a homodimer or heterodimer with EID-2. Biochem. Biophys. Res. Commun. 2005:333:969-975.
  6. Sakai H, Jinawath A, Yamaoka S, Yuasa Y: Upregulation of MUC6 mucin gene expression by NF- kB and Sp factors. Biochem. Biophys. Res. Commun. 2005:333:1254-1260.
  7. Galm O, Suzuki H, Akiyama Y, Esteller M, Malcolm MV, Osieka R, Baylin SB, Herman JG: Inactivation of the tissue inhibitor of metallortoteinases-2 gene by promoter hypermethylation in lymphoid malignancies. Oncogene 2005:24:4799-4805.
  8. Fukamachi H, Narita T, Yahagi N, Takeda H, Ichinose M. Endothelin-3 controls growth of colonic epithelial cells by mediating epithelial-mesenchymal interaction. Develop. Growth Differ. 2005:47:572-580.
  9. Ohsugi M, Kuroki K, Fukamachi H, O'Reilly LA, Kuida K, Strasser A, Yonehara, S. Transforming growth factor-β-dependent sequential activation of Smads, Bim and caspase-9 mediates physiological apoptosis in gastric epithelial cells. Mol. Cell. Biol. 2005:25:10017-10028.
  10. Tanaka S, Shimada M, Shirabe K, Maehara Si, Tsujita E, Taketomi A, Maehara Y. Surgical outcome of patients with hepatocellular carcinoma originating in the caudate lobe. American Journal of Surgery, 190(3);451-55, 2005
  11. Tanaka S, Shimada M, Shirabe K, Maehara Si, Harimoto N, Tsujita E, Sugimachi K, Maehara Y. A novel intrahepatic arterial chemotherapy after radical resection for advanced hepatocellular carcinoma. Hepatogastroenterology, 52(63):862-5, 2005.
  12. Tanaka S. CCN4 and CCN6 variants in Wnt-inducible signaling pathway. in CCN proteins: A new family of cell growth and differentiation regulators, ed. Perbal P, Takigawa M. Pp293-304, (Imperial College Press, London), 2005
  13. Sakai S, Kawabata K, Tanaka S, Harimoto N, Hashimoto I, Mu C, Salmons B, Iijima H, Kasakami K. Subsieve-size agarose capsules enclosing ifosfamide-activating cells: a strategy towards chemotherapeutic targeting to tumors. Molecular Cancer Therapeutics, 4(11):1786-90, 2005.
  14. Itoh S, Ohga T, Saeki H, Nakamura T, Watanabe M, Tanaka S, Kakeji Y, Maehara Y. p53 mutation profiling of multiple esophageal carcinoma using laser capture microdissection to demonstate field carcinogenesis. International Journal of Cancer, 113(1):22-8, 2005
  15. Harimoto N, Taketomi A, Kitagawa D, Kuroda Y, Itoh S, Gion T, Tanaka S, Shirabe K, Shimada M, Maehara Y. The newly established human hepatocyte cell line: Application for the bioartificial liver: Hepatocyte differentiation therapy for the bioartificial liver. Journal of Hepatology, 42(4):557-64, 2005
  16. Merle P, Kim M, Herrmann M, Gupte A, Lefrancois L, Califano S, Trepo C, Tanaka S, Vitvitski L, Monte SD, Wands JR. Oncogenic role of the frizzled-7/beta-catenin pathway in hepatocellular carcinoma. Journal of Hepatology, 43(5):854-62, 2005

2004

  1. Li X-L, Eishi Y, Bai Y-Q, Sakai H, Akiyama Y, Tani M, Takizawa T, Koike M, Yuasa Y: Expression of the SRY-related HMG box protein SOX2 in human gastric carcinoma. Int. J. Oncology 2004:24:257-263
  2. Sakai H, Eishi Y, Li X-L, Akiyama Y, Miyake S, Takizawa T, Konishi N, Tatematsu M, Koike M, Yuasa Y: PDX1 homeobox protein expression in pseudopyloric glands and gastric carcinomas. Gut 2004:53:323-330.
  3. Ren C-Y, Akiyama Y, Miyake S, Yuasa Y: Transcription factor GATA-5 selectively up-regulates mucin gene expression. J. Cancer Res. Clin. Oncol., 2004:130:245-252.
  4. Wen X-Z, Miyake S, Akiyama Y, Yuasa Y: BMP-2 modulates the proliferation and differentiation of normal and cancerous gastric cells. Biochem. Biophys. Res. Commun., 2004:316:100-106.
  5. Douglas DB, Akiyama Y, Esteller M, Gabrielson E, Weitzman S, Williams T, Herman JG, Baylin SB: Hypermethylation of a small CpGuanine-rich region correlates with loss of activator protein-2alpha during progression of breast cancer. Cancer Res., 2004:64:1611-1620.
  6. Suzuki H, Watkins DN, Jair K-M, Schuebel KE, Markowitz SD, Chen W-D, Pretlow TP, Yang B, Akiyama Y, van Engeland M, Toyota M, Tokino T, Hinoda Y, Imai K, Herman JG, Baylin SB: Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat. Genet., 2004:36:582-584.
  7. Guo M, Akiyama Y, House MG, Hooker CM, Heath E, Gabrielson E, Yang SC, Han Y, Baylin SB, Herman JG , Brock MV: Hypermethylation of the GATA Genes in Lung Cancer. Clini. Cancer Res., 2004:10:7917-7924.
  8. Ryu GH, Tanaka H, Kim DH, Kim JH, Bae SH, Kwon YN, Rhee JS, MacNeill SA, Seo YS: Genetic and biochemical analyses of Pfh1 DNA helicase function in fission yeast. Nucleic Acids Res., 2004:32:42054216.
  9. Tanaka H, Ryu GH, Seo YS, MacNeill SA: Genetics of lagging strand DNA synthesis and maturation in fission yeast: suppression analysis links the Dna2-Cdc24 complex to DNA polymerase delta. Nucleic Acids Res., 2004:32:6367-6377.
  10. Merle P, de la Monte S, Kim M, Herrmann M, Tanaka S, Von Dem Bussche A, Kew MC, Trepo C, Wands JR. Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology, 127(4):1110-22, 2004
  11. Itoh S, Maeda T, Aishima Si, Shirabe K, Tanaka S, Maehara Y. Role of expression of focal adhesion kinase on progression in hepatocellular carcinoma. Clinical Cancer Research, 10(8):2812-7, 2004
  12. Yamashita Y, Shimada M, Minagawa R, Tsujita E, Harimoto N, Tanaka S, Shirabe K, Miyazaki J, Maehara Y. Muscle-targeted interleukin-12 gene therapy of orthotopic hepatocellular carcinoma in mice using in vivo electrosonoporation. Molecular Cancer Therapeutics, 3(9):1177-82, 2004
  13. Maehara Si, Tanaka S, Saito , Shirabe K, Maehara Y. Selenoprotein P, as a predictor for evaluating gemcitabine resistance in human pancreatic cancer cells. International Journal of Cancer, 112(2):184-9, 2004
  14. Osoegawa A, Yoshino I, Tanaka S, Sugio K, Kameyama T, Yamaguchi M, Maehara Y. Regulation of p27 by S-phase kinase-associated protein 2 is associated with aggressiveness in non-small-cell lung cancer. Journal of Clinical Oncology, 22(20):4165-73, 2004

2003

  1. Miyake S, Yanagisawa Y, Yuasa Y: A novel EID-1 family member, EID-2, associates with histone deacetylases and inhibits muscle differentiation. J. Biol. Chem. 2003:278:17060-17065.
  2. Bai Y-Q, Miyake S, Iwai T, Yuasa Y: CDX2, a homeobox transcription factor, up-regulates transcription of the p21/WAF1/CIP1 gene. Oncogene 2003:22:7942-7949.
  3. Yamamoto H, Bai Y-Q, Yuasa Y: Homeodomain protein CDX2 regulates goblet-specific MUC2 gene expression. Biochem. Biophys. Res. Commun. 2003:300:813-818.
  4. Ishikawa T, Fujita T, Suzuki Y, Okabe S, Yuasa Y, Iwai T, Kawakami Y: Tumor-specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability. Cancer Res. 2003:63:5564-5572.
  5. Brock MV, Gou M, Akiyama Y, Muller A, Wu T-T, Montgomery E, Deasel M, Germonpre P, Rubinson L, Heitmiller RF, Yang SC, Forastiere AA, Baylin SB & Herman JG. Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clinical Cancer Res. 2003:9:2912-2919.
  6. Akiyama Y, Watkins N, Suzuki H, Jair K-W, van Engeland M, Esteller M, Sakai H, Ren C-Y, Yuasa Y, Herman JG and Baylin SB: GATA-4 and GATA-5 transcription factor genes and potential downstream anti-tumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol. Cell. Biol. 2003:23:8429-8439.
  7. Xie GX, Han X, Ito E, Yanagisawa Y, Maruyama K, Sugano S, Suzuki Y, Wang Y, Gabriel A, Stevens SK, Mitchell J, Sharma M, Palmer PP. Gene structure, dual-promoters and mRNA alternative splicing of the human and mouse regulator of G protein signaling GAIP/RGS19. J. Mol. Biol. 2003:325:721-732.
  8. Tanaka S, Sugimachi K, Kameyama T, Maehara Si, Shirabe K, Shimada M, Wands JR, Maehara Y. Human WISP1v, a member of CCN family, is associated with invasive cholangiocarcinoma. Hepatology, 37(5):1122-9, 2003
  9. Tanaka S, Sugimachi K, Maehara Si, Shimada M, Maehara Y. A loss of function mutation in WISP3 derived from microsatellite unstable gastric carcinoma. Gastroenterology, 125(5): 1563-4, 2003
  10. Tanaka S, Sugimachi K, Yamashita Yi, Shirabe K, Shimada M, Wands JR, Sugimachi K. Angiogenic switch as a molecular target of malignant tumors. Journal of Gastroenterology, 38 (Suppl 15):93-7, 2003
  11. Yamashita Yi, Shimada M, Harimoto N, Rikimaru T, Shirabe K, Tanaka S, Sugimachi K. Histone deacetylase inhibitor Trichostatin A induces cell cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells. International Journal of Cancer, 103(5):572-6, 2003
  12. Sugimachi K, Tanaka S, Kameyama T, Taguchi Ki, Aishima Si, Shimada M, Sugimachi K, Tsuneyoshi M. The transcriptional repressor Snail and progression of human hepatocellular carcinoma. Clinical Cancer Research, 9(7):2657-64, 2003
  13. Sugimachi K, Tanaka S, Taguchi Ki, Shimada M, Sugimachi K, Tsuneyoshi M. Angiopoietin switching regulates angiogenesis and progression of human hepatocellular carcinoma. Journal of Clinical Pathology, 56(11):854-60, 2003
  14. Yuasa Y: Control of gut differentiation and intestinal type gastric carcinogenesis. Nature Rev. Cancer 2003:3:592-600.
  15. Dominant negative mutants of IRS-1 and uses thereof
    Tanaka S, Wands JR (2003)

2002

  1. Bai Y-Q, Yamamoto H, Akiyama Y, Tanaka H, Takizawa T, Koike M, Yagi OK, Saitoh K, Takeshita K, Iwai T, Yuasa Y: Ectopic expression of homeodomain protein CDX2 in intestinal metaplasia and carcinomas of the stomach. Cancer Letters 2002:176:47-55.
  2. Hiwasa T, Shimada H, Ochiai T, Liu T-L, Yuasa Y, Takiguchi M, Ohkoshi M: Decrease in growth factor receptors after treatment with serine protease inhibitor ONO-3403. Int. J. Oncol.2002:20:797-802.
  3. Homma MK, Li D, Krebs EG, Yuasa Y, Homma Y: Association and regulation of casein kinase 2 activity by adenomatous polyposis coli protein. Proc. Natl. Acad. Sci. U.S.A. 2002:99:5959-5964.
  4. Yanagisawa Y, Ito E, Yuasa Y, Maruyama K: DNA methyltransferases DNMT3A and DNMT3B have two types of promoters with different CpG contents. Biochimica Biophysica Acta 2002:1577:457-465.
  5. Tanaka H, Ryu G-H, Seo Y-S, Tanaka K, Okayama H, MacNeill SA, Yuasa Y: The fission yeast pfh1+ gene encodes an essential 5' to 3' DNA helicase require for the completion of S-phase. Nucleic Acids Research 2002:30:4728-4739.
  6. Nakajima Y, Nagai K, Miyake S, Ohashi K, Kawano T, Iwai T, Evaluation of an indicator for lymph node metastasis of esophageal squamous cell carcinoma invading the submucosal layer. Jpn J Cancer Res, 2002:93:305-312.
  7. Tanaka S, Sugimachi K, Yamashita Yi, Ohga T, Shirabe K, Shimada M, Wands JR, Sugimachi K. Tie2 vascular endothelial receptor expression and function in hepatocellular carcinoma. Hepatology, 35(4): 861-7, 2002
  8. Tanaka S, Sugimachi K, Shimada M, Maehara Y, Sugimachi K. Variant WISPs as targets for gastrointestinal carcinomas. Gastroenterology, 123(1): 392-3, 2002
  9. Tanaka S, Sugimachi K, Maehara Si. Shirabe K, Shimada M, Wands JR, Sugimachi K. Oncogenic signal transduction and therapeutic strategy for hepatocellular carcinoma. Surgery, 131(1 Pt 2):S142-7, 2002
  10. Yamashita Yi, Shimada M, Tanaka S, Okamoto M, Miyazaki Ji, Sugimachi K. Electroporation-mediated tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L gene therapy for hepatocellular carcinoma. Human Gene Therapy, 13(2): 275-86, 2002
  11. Sugimachi K, Tanaka S, Terashi T. Taguchi K, Shimada M, Sugimachi K. The mechanisms of angiogenesis in hepatocellular carcinoma: Angiogenic switch during tumor progression. Surgery, 131(1 Pt 2):S135-41, 2002
  12. Yuasa Y: DNA methylation in cancer and ageing. Mechanisms of Ageing and Development 2002:123:1649-1654.

2001

  1. Nakajima T, Akiyama Y, Shiraishi J, Arai T, Yanagisawa Y, Ara M, Fukuda Y, Sawabe M, Saitoh K, Kamiyama R, Hirokawa K, Yuasa Y: Age-related hypermethylation of the hMLH1 promoter in gastric cancers. Int. J. Cancer 2001:94:208-211.
  2. Esteller M, Fraga MF, Guo M, Garcia-Foncillas J , Hedenfalk I, Godwin AK, Trojan J, Vaurs-Barriere C, Bignon Y-J, Ramus S, Benitez J, Caldes T, Akiyama Y, Yuasa Y, Launonen V, Canal MJ, Rodriguez R, Capella G, Peinado MA, Borg A, Aaltonen LA, Ponder BA, Baylin SB, Herman JG: DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Human Molecular Genetics 2001:10:3001-3007.
  3. Sato Y, Akiyama Y, Tanizawa T, Shibata T, Saito K, Mori S, Kamiyama R, Yuasa Y: Molecular characterization of the genomic breakpoint junction in the t(11;18)(q21;q21) translocation of a gastric MALT lymphoma. Biochem. Biophys. Res. Commun. 2001:280:301-306.
  4. Akiyama Y, Nagasaki H, Nakajima T, Sakai H, Nomizu T, Yuasa Y: Infrequent frameshift mutations in the simple repeat sequences of hMLH3 in hereditary nonpolyposis colorectal cancers. Jpn. J. Clinical Oncology 2001:31:61-64.
  5. Kai M, Tanaka H, Wang TS: Fission yeast rad17 associates with chromatin in response to aberrant genomic structures. Molecular and Cellular Biology 2001:21:3289-3301.
  6. Nakajima Y, Miyake S, Nagai K, Kawano T, Iwai T: CPT-11 may provide therapeutic efficacy for esophageal squamous cell cancer and the effects correlate with the level of DNA Topoisomerase I protein. Jpn. J. Cancer Res. 2001:92:1335-1341.
  7. Tanaka S, Ueo H, Mafune K, Mori M, Wands JR, Sugimachi K. A novel isoform of human fibroblast growth factor 8 is induced by androgens and associated with progression of esophageal carcinoma. Digestive Diseases and Sciences, 46(5): 1016-21, 2001
  8. Tanaka S, Sugimachi K, Saeki H, Kinoshita J, Ohga T, Shimada M, Maehara Y, Sugimachi K. A novel variant of WISP1 lacking a Von Willebrand type C module overexpressed in scirrhous gastric carcinoma. Oncogene, 20(39): 5525-32, 2001
  9. Yamashita Yi, Shimada M, Hamatsu T, Rikimaru T, Tanaka S, Shirabe K, Sugimachi K. Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model. Cancer Research, 61(3): 1005–1012, 2001
  10. Etoh T, Inoue H, Tanaka S, Bernard GF, Kitano S, Mori M. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: Possible in vivo regulation via induction of proteases. Cancer Research, 61(5): 2145-2153, 2001
  11. Sugimachi K, Taguchi Ki, Aishima Si, Tanaka S, Shimada M, Kajiyama K, Sugimachi K, Tsuneyoshi. Altered expression of beta-catenin without genetic mutation in intrahepatic cholangiocarcinoma. Modern Pathology, 14(9): 900-5, 2001
  12. Sugimachi K, Aishima S, Taguchi K, Tanaka S, Shimada M, Kajiyama K, Sugimachi K, Tsuneyoshi M. The role of overexpression and gene amplification of cyclin D1 in intrahepatic cholangiocarcinoma. Journal of Hepatology, 35(1): 74-79, 2001
  13. Kinoshita J, Kitamura K, Kanashima A, Saeki H, Tanaka S, Sugimachi K. Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer. Breast Cancer Research and Treatment, 66(2): 159-64, 2001
  14. Yamashita Yi, Hamatsu T, Rikimaru T, Tanaka S, Shirabe K, Shimada M, Sugimachi K. Bile leakage after hepatic resection. Annals of Surgery, 233(1): 45-50, 2001
  15. Yamashita Y, Shimada M, Tsujita E, Tanaka S, Ijima H, Nakazawa K, Sakiyama R, Fukuda J, Ueda T, Funatsu K, Sugimachi K. Polyurethane foam/spheroid culture system using human hepatoblastoma cell line (Hep G2) as a possible new hybrid artificial liver. Cell Transplantion, 10(8):717-22, 2001

2000

  1. Bai Y-Q, Akiyama Y, Nagasaki H, Yagi OK, Kikuchi Y, Saito N, Takeshita K,  Iwai T, Yuasa Y: Distinct expression of CDX2 and GATA4/5, development-related genes, in human gastric cancer cell lines. Molecular Carcinogenesis 2000:28:184-188.
  2. Yanagisawa Y, Akiyama Y, Iida S, Ito E, Nomizu T, Sugihara K, Yuasa Y, Maruyama K: Methylation of the hMLH1 promoter in familial gastric cancer with microsatellite instability. Int. J. Cancer 2000:85:50-53.
  3. Iida S, Akiyama Y, Nakajima T, Ichikawa W, Nihei Z, Sugihara K, Yuasa Y: Alterations and hypermethylation of the p14ARF gene in gastric cancers. Int. J. Cancer 2000:87:654-658
  4. Akiyama Y, Nagasaki H, Yagi OK, Nomizu T, Yuasa Y: -catenin and adenomatous polyposis coli (APC) mutations in adenomas from hereditary nonpolyposis colorectal cancer patients. Cancer Letters 2000:157:185-191.
  5. Furihata M, Shuin T, Takeuchi T, Sonobe H, Ohtsuki Y, Akiyama Y, Yuasa Y: Missense mutation of the hMSH6 and p53 genes in sporadic urothelial transitional cell carcinoma. Int. J. Oncology 2000:16:491-496.
  6. Suzuki L, Woessner JP, Uchida H, Kuroiwa H, Yuasa Y, Waffenschmidt S, Goodenough UW, Kuroiwa T: A zygote-specific protein with hydroxyproline-rich glycoprotein domains and lectin-like domains involved in the assembly of the cell wall of Chlamydomonas reinhardt. (chlorophyta). J. Phycol. 2000:36:571-583.
  7. Yuasa Y: Molecular genetics of colorectal and gastric cancers. J. Clinical Biochemistry and Nutrition, 2000:28:167-175.
  8. Tanaka S, Mori M, Mafune K, Ohno S, Sugimachi K A dominant negative mutation of transforming growth factor-beta receptor type II in microsatellite stable oesophageal carcinoma. British Journal of Cancer, 82(9): 1557-1560, 2000
  9. Tanaka S, Sugimachi K, Kawaguchi H, Saeki H, Ohno S, Wands JR, Sugimachi K. Grb7 signal transduction protein mediates metastatic progression of esopahgeal carcinoma. Journal of Cellular Physiology, 183(3): 411-415, 2000
  10. Tanaka S, Sugimachi K, Shirabe K, Shimada M, Wands JR, Sugimachi K. Expression and anti-tumor effects of TRAIL in human cholangiocarcinoma. Hepatology, 32(3): 523-527, 2000
  11. Kawaguchi H, Ohno S, Araki K, Miyazaki M, Saeki H, Watanabe M, Tanaka S, Sugimachi K. p53 polymorphism in human papillomavirus-associated esophageal cancer. Cancer Research, 60(11): 2753-2755, 2000.

1999

  1. Yagi OK, Akiyama Y, Yuasa Y: Genomic structure and alterations of homeobox gene CDX2 in colorectal carcinomas.
    British Journal of Cancer 1999:79:440-444.
  2. Ito E, Iwahashi Y, Yanagisawa Y, Suzuki Y, Sugano S, Yuasa Y, Maruyama K: Two short sequences have positive effects on the human p27kip1 gene transcription.
    Gene 1999:228:93-100.
  3. Ito E, Yanagisawa Y, Iwahashi Y, Suzuki Y, Nagasaki H, Akiyama Y, Sugano S, Yuasa Y, Maruyama K: A core promoter and a frequent single-nucleotide polymorphism of the mismatch repair gene hMLH1.
    Biochem. Biophys. Res. Commun. 1999:256:488-494.
  4. Bai Y-Q, Akiyama Y, Nagasaki H, Lu S-L, Arai T, Morisaki T, Kitamura M, Muto A, Nagashima M, Nomizu T, Iwama T, Itoh H, Baba S, Iwai T, Yuasa Y: Predominant germline mutation of the hMSH2 gene in Japanese hereditary nonpolyposis colorectal cancer kindreds.
    International J. Cancer, 1999:82:512-515.
  5. Iida S, Akiyama Y, Ichikawa W, Yamashita T, Nomizu T, Nihei Z, Sugihara K, Yuasa Y: Infrequent germline mutation of the E-cadherin gene in Japanese familial gastric cancer kindreds.
    Clinical Cancer Research, 1999:5:1445-1447.
  6. Lu S-L, Kawabata M, Imamura T, Miyazono K, Yuasa Y: Two divergent signaling pathways for TGF- separated by a mutation of its type II receptor gene.
    Biochem. Biophys. Res. Commun. 1999:259:385-390.
  7. Bruder CEG, Ichimura K, Tingby O, Hirakawa K, Komatsuzaki A, Tamura A, Yuasa Y, Collins VP, Dumanski JP: A group of schwannomas with interstitial deletions on 22q located outside the NF2 locus shows no detectable mutations in the NF2 gene.
    Human Genetics 1999:104:418-424.
  8. Bruder CEG, Ichimura K, Blennow E, Ikeuchi T, Yamaguchi T, Yuasa Y, Collins VP, Dumanski JP: Severe phenotype of neurofibromatosis type 2 in a patient with a 7.4-MB constitutional deletion on chromosome 22: Possible localization of a neurofibromatosis type 2 modifier gene?
    Genes, Chromosomes & Cancer 1999:25:184-190.
  9. Arai T, Akiyama Y, Nagasaki H, Murase N, Okabe S, Ikeuchi T, Saito K, Iwai T, Yuasa Y: EXTL3/EXTR1 alterations in colorectal cancer cell lines.
    International J. Oncology 1999:15:915-919.
  10. Akiyama Y, Arai T, Nagasaki H, Yagi OK, Nakahata A, Nakajima T, Ohkura Y, Iwai T, Saitoh K, Yuasa Y: Frequent allelic imbalance on chromosome 18q21 in early superficial colorectal cancers.
    Jpn. J. Cancer Res. 1999:90:1329-1337.
  11. Maruyama M, Nagahama T, Yuasa Y: Intraperitoneal versus intravenous CPT-11 for peritoneal seeding and liver metastasis.
    Anticancer Res. 1999:19:4187-4192.
  12. Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands JR. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. Journal of Clinical Investigation, 103(3): 341-5, 1999
  13. Shibata K, Tanaka S, Shiraishi T, Kitano S, Mori M. G-protein gamma 7 is down-regulated in cancers and associated with p 27kip1-induced growth arrest. Cancer Research, 59(5): 1096-101, 1999
  14. Fujie T, Tanaka F, Tahara K, Li J, Tanaka S, Mori M, Ueo H, Takesako K, Akiyoshi T. Generation of specific antitumor reactivity by the stimulation of spleen cells from gastric cancer patients with MAGE-3 synthetic peptide. Cancer Immunology and Immunotherapy, 48(4): 189-94, 1999

1998

  1. Arai T, Akiyama Y, Okabe S, Ando M, Endo M, Yuasa Y: Genomic structure of the human Smad3 gene and its infrequent alterations in colorectal cancers.
    Cancer Letters 1998:122:157-163.
  2. Yagi OK, Akiyama Y, Nomizu T, Iwama T, Endo M, Yuasa Y: Proapoptotic gene BAX is frequently mutated in hereditary nonpolyposis colorectal cancers but not in adenomas.
    Gastroenterology 1998:114:268-274.
  3. Akiyama Y, Yagi OK, Ishikawa T, Nagasaki H, Saitoh K, Yuasa Y: Genetic alterations are frequent in APC but rare in the TGF- type II receptor gene in cancer in adenoma of the colon.
    Cancer Letters 1998:125:89-96.
  4. Yanagisawa Y, Ito E, Iwahashi Y, Akiyama Y, Yuasa Y, Maruyama K: Isolation and characterization of the 5' region of the human mismatch repair gene hPMS1.
    Biochem. Biophys. Res. Commun. 1998:243:738-743.
  5. Tahara S, Tanaka K, Yuasa Y, Okayama H: Functional domains of Rep2, a transcriptional activator subunit for Res2-Cdc10, controlling the cell cycle "start".
    Molecular Biology of the Cell 1998:9:1577-1588.
  6. Lu S-L, Kawabata M, Imamura T, Akiyama Y, Nomizu T, Miyazono K, Yuasa Y: HNPCC associated with germline mutation in the TGF- type II receptor gene.
    Nature Genetics 1998:19:17-18.
  7. Arai T, Akiyama Y, Yamamura A, Hosoi T, Shibata T, Saitoh K, Okabe S, Yuasa Y: Allelotype analysis of early colorectal cancers with lymph node metastasis.
    International J. Cancer 1998:79:418-423.
  8. Iwahashi Y, Ito E, Yanagisawa Y, Akiyama Y, Yuasa Y, Onodera T, Maruyama K: Promoter analysis of the human mismatch repair gene hMSH2.
    Gene 1998:213:141-147.
  9. Arai T, Akiyama Y, Okabe S, Saito K, Iwai T, Yuasa Y: Genomic organization and mutation analysis of the DR5/TRAIL receptor 2 gene in colorectal carcinoma.
    Cancer Letters 1998:133:197-204.
  10. Ikezoe T, Takeuchi S, Arai T, Yuasa Y, Taguchi H: Analysis of the Smad3 gene in hematological malignancies.
    International J. Hematology 1998:68:457-458.
  11. Tanaka S, Akiyoshi T, Mori M, Wands JR, Sugimachi K. A novel frizzled gene identified in human esophageal carcinoma mediates APC/beta-catenin signals. Proceedings of the National Academy of Sciences, USA, 95(17): 10164-10169, 1998
  12. Tanaka S, Mori M, Akiyoshi T, Tanaka Y, Mafune K, Wands JR, Sugimachi K. A novel variant of human Grb7 is associated with invasive esophageal carcinoma. Journal of Clinical Investigation, 102(4): 821-827, 1998
  13. Yonemitsu Y, Kaneda Y, Tanaka S, Nakashima Y, Komori K, Sugimachi K, Sueishi K. Transfer of wild-type p53 gene effectively inhibits vascular smooth muscle cell proliferation in vitro and in vivo. Circulation Research, 82(2): 147-156, 1998
  14. Mohr L, Tanaka S, Wands JR. Ethanol inhibits hepatocytes proliferation through the IRS-1 signal transduciton pathway in transgene mice. Gastroenterology, 115(6): 1558-65, 1998

1997

  1. Akiyama Y, Iwanaga R, Saitoh K, Shiba K, Ushio K, Ikeda E, Iwama T, Nomizu T, Yuasa Y: Transforming growth factor- type II receptor gene mutations in adenomas from hereditary nonpolyposis colorectal cancer patients. Gastroenterology 1997:112:33-39.
  2. Oto M, Koguchi A, Yuasa Y: Analysis of a polyadenine tract of the TGF- type II receptor gene in colorectal cancers by non-gel sieving capillary electrophoresis. Clinical Chemistry 1997:43:759-763.
  3. Yagi OK, Akiyama Y, Ohkura Y, Ban S, Endo M, Saitoh K, Yuasa Y: Analyses of the APC and TGF- type II receptor genes, and microsatellite instability in mucosal colorectal carcinomas. Jpn. J. Cancer Res. 1997:88:718-724.
  4. Akiyama Y, Tsubouchi N, Yuasa Y: Frequent somatic mutations of hMSH3 with reference to microsatellite instability in hereditary nonpolyposis colorectal cancers. Biochem. Biophys. Res. Commun. 1997:236:248-252.
  5. Hori H, Kawano T, Endo M, Yuasa Y: Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and human esophageal squamous cell carcinoma susceptibility. Journal of Clinical Gastroenterology 1997:25:568-575.
  6. Akiyama Y, Sato H, Yamada T, Nagasaki H, Tsuchiya A, Abe R, Yuasa Y: Germline mutation of the hMSH6/GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred. Cancer Research 1997:57:3920-3923.
  7. Suzuki L, Yuasa Y, Kuroiwa T: Transcription and translation involved in pellicle formation in the Chlamydomonas reinhardtii zygote. Cytologia 1997:62:421-425.
  8. Suzuki L, Yuasa Y, Kuroiwa T: Transcription and translation involved in uniparental inheritance and cell nuclei fusion in the Chlamydomonas reinhardtii zygote. Cytologia 1997:62:427-433.
  9. Tanaka S, Mori M, Akiyoshi T, Tanaka Y, Mafune K, Wands JR, Sugimachi K. Co-expression of Grb7 with EGFR or Her2/erbB2 in human advanced esophageal carcinoma. Cancer Research, 57(1): 28-31, 1997
  10. Tanaka S, Smidt EV, Mohr L, Sugimachi K, Wands JR. Biological effects of human insulin receptor substrate-1 overexpression in hepatocytes. Hepatology, 26(3): 598-604, 1997
  11. Mori M, Mimori K, Shiraishi T, Tanaka S, Ueo H, Sugimachi K, Akiyoshi T. p27 expression and gastric carcinoma. Nature Medicine, 3(6): 593, 1997

1996

  1. Sasaki A, Nagashima M, Shiseki M, Katai H, Maruyama K, Iwanaga R, Akiyama Y, Yuasa Y, Yokota J: Microsatellite instability in gastric cancer prone families.
    Cancer Letters 1996:99:169-175.
  2. Homma MK, Homma Y, Yamasaki M, Ohmi-Imajoh S, Yuasa Y: Growth inhibition by phospholipase C inhibitor peptides of colorectal carcinoma cells derived from familial adenomatous polyposis.
    Cell Growth & Differentiation 1996:7:281-288.
  3. Lu S-L, Akiyama Y, Nagasaki H, Nomizu T, Ikeda E, Baba S, Ushio K, Iwama T, Maruyama K, Yuasa Y: Loss or somatic mutations of hMSH2 occur in hereditary nonpolyposis colorectal cancers with hMSH2 germline mutations.
    Jpn. J. Cancer Res. 1996:87:279-287.
  4. Akiyama Y, Nagasaki H, Nihei Z, Iwama T, Nomizu T, Yuasa Y: Frequent microsatellite instabilities and analyses of the related genes in familial gastric cancers.
    Jpn. J. Cancer Res. 1996:87:595-601.
  5. Yuasa Y, Akiyama Y, Lu S-L, Wu C, Nagasaki H, Nomizu T, Baba S, Ushio K, Iwama T, Nakabeppu Y, Sekiguchi M: Analysis of the hMSH2 and hMTH1 genes in hereditary nonpolyposis colorectal cancer. "New Strategies for Treatment of Hereditary Colorectal Cancer" ed. Shozo Baba.
    Churchill Livingstone Japan, 1996:99-114.
  6. Hori H, Miyake S, Akiyama Y, Endo M, Yuasa Y: Clonal heterogeneity in human esophageal squamous cell carcinomas on DNA analysis.
    Jpn. J. Cancer Res. 1996:87:923-929.
  7. Lu S-L, Zhang W-C, Akiyama Y, Nomizu T, Yuasa Y: Genomic structure of the transforming growth factor type II receptor gene and its mutations in hereditary nonpolyposis colorectal cancers.
    Cancer Research 1996:56:4595-4598.
  8. Akiyama Y, Iwanaga R, Ishikawa T, Sakamoto K, Nishi N, Nihei Z, Iwama T, Saitoh K, Yuasa Y: Mutations of the transforming growth factor- type II receptor gene are strongly related to sporadic proximal colon cancers with microsatellite instability.
    Cancer 1996:78:2478-2484.
  9. Tanaka S, Takenaka K, Matsumata T, Mori R, Sugimachi K. Hepatitis C virus replication is associated with expression of transforming growth factor-alpha and insulin-like growth factor-II in cirrhotic livers. Digestive Diseases and Sciences, 41(1): 208-15, 1996
  10. Tanaka S, Ito T, Wands JR. Neoplastic transformation induced by insulin receptor substrate-1 overexpression requires an interaction with Grb2 and Syp signaling molecules. Journal of Biological Chemistry, 271(24): 14610-6, 1996
  11. Tanaka S, Wands JR. A carboxy-terminal truncated IRS-1 dominant negative protein reverses the human hepatocellular carcinoma malignant phenotype. Journal of Clinical Investigation, 98(9): 2100-8, 1996
  12. Tanaka S, Wands JR. Insulin receptor substrate-1 overexpression in human hepatocellular carcinoma cells prevents transforming growth factor-beta1 induced apoptosis. Cancer Research, 56(15): 3391-4, 1996

1995

  1. Oto M, Suehiro T, Akiyama Y, Yuasa Y: Microsatellite instability in cancer identified by non-gel sieving capillary electrophoresis. Clinical Chemistry. 1995:41:482-483.
  2. Oto M, Suehiro T, Yuasa Y: DNA hybridization analysis of PCR products by non-gel sieving capillary electrophoresis. PCR Methods & Applications. 1995:4:303-304.
  3. Oto M, Suehiro T, Yuasa Y: Identification of mutated p53 in cancer by non-gel sieving capillary electrophoretic SSCP analysis. Clinical Chemistry. 1995:41:1787-1788.
  4. Wu C, Nagasaki H, Maruyama K, Nakabeppu Y, Sekiguchi M, Yuasa Y: Polymorphisms and probable lack of mutation in a human mutT homolog, hMTH1, in hereditary nonpolyposis colorectal cancer. Biochem. Biophys. Res. Commun. 1995:214:1239-1245.
  5. Lu S-L, Akiyama Y, Nagasaki H, Saitoh K, Yuasa Y: Mutations of the transforming growth factor- type II receptor gene and genomic instability in hereditary nonpolyposis colorectal cancer. Biochem. Biophys. Res. Commun. 1995:216:452-457.
  6. Yamada T, Terada Y, Homma MK, Nonoguchi H, Sasaki S, Yuasa Y, Tomita K, Marumo F: AVP inhibits EGF-stimulated MAP kinase cascade in Madin-Darby canine kidney cells. Kidney International. 1995:48:745-752.
  7. Terada Y, Tomita K, Homma MK, Nonoguchi H, Yang T, Yamada T, Yuasa Y, Krebs EG, Marumo F: Sequential activation of MAP kinase cascade by angiotensin II in opossum kidney cells. Kidney International. 1995:48:1801-1809.

1994

  1. Wu C, Akiyama Y, Imai K, Miyake S, Nagasaki H, Oto M, Okabe S, Iwama T, Mitamura K, Masumitsu H, Nomizu T, Baba S, Maruyama K, Yuasa Y : DNA alterations in cells from hereditary non-polyposis colorectal cancer patients. Oncogene. 1994: 9: 991-994.
  2. Homma MK, Homma Y, Namba M, Yuasa Y: Enhanced phosphoinositide metabolism in colorectal carcinoma cells derived from familial adenomatous polyposis patients. Journal of Cellular Biochemistry. 1994: 55: 477-485.
  3. Miyake S, Nagai K, Yoshino K, Oto M, Endo M, Yuasa Y : Point mutations and allelic deletion of tumor suppressor gene DCC in human esophageal squamous cell carcinomas and their relation to metastasis. Cancer Reserch. 1994: 54 : 3007-3010.
  4. Arai T, Ichimura K, Hirakwa K, Yuasa Y: DNA amplifications and elevated expression of proto-oncogene in addition to altered DNA ploidy in metastatic brain tumors. Clinical and Experimental Metastasis. 1994: 12: 267-275.
  5. Terada Y, Tomita K, Homma MK, Nonoguchi H, Yang T, Yamada T, Yuasa Y, Krebs EG, Sasaki S, Marumo F : Sequential activation of Raf-1 kinase, mitogen-activated protein (MAP) kinase kinase, MAP kinase, and S6 kinase by hyperosmolarity in renal cells. J. Biol. Chem. 1994: 269: 31296-31301.
  6. Maruyama K, Sugano S: Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNA with oligoribonucleotides. Gene. 1994: 138: 171-174.
  7. Nara K, Watanabe Y, Maruyama K, Kasahara K, Nagai Y, Sanai Y : Expression cloning of a CMP-NeuAc:NeuAc alpha 2-3Gal beta 1-4Glc beta 1-1′Cer alpha 2, 8-sialyltransferase (GD3synthase) from human melanoma cells. Proc Natl Acad Sci U S A. 1994:91(17): 7952-7956.
  8. Shimane M, Tani K, Maruyama K, Takahashi S, Ozawa K, Asano S : Molecular cloning and characterization of G-CSF incuced gene cDNA. Biochem. Biophys. Res. Commun. 1994: 199(1) : 26-32.
  9. Tanaka S, Komori K, Okadome K, Sugimachi K, Mori R. Detection of active cytomegalovirus infection in inflammatory aortic aneurysms with RNA polymerase chain reaction. Journal of Vascular Surgery, 20(2): 235-43, 1994
  10. Tanaka S, Minagawa H, Toh Y, Liu Y, Mori R. Analysis by RNA-PCR of latency and reactivation of herpes simplex virus in multiple neuronal tissues. Journal of General Virology,75(11): 2691-8, 1994

1993

  1. Tanaka S, Toh Y, Adachi E, Matsumata T, Mori R, Sugimachi K. Tumor progression in hepatocellular carcinoma may be mediated by p53 mutation. Cancer Research,53: 2884-7, 1993
  2. Tanaka S, Toh Y, Mori R. Molecular analysis of a neurovirulent herpes simplex virus type 2 strain with reduced thymidine kinase activity. Archives of Virology, 131: 61-73, 1993

1992

  1. Tanaka S, Toh Y, Minagawa H, Mori R, Sugimachi K, Minamishima Y. Reactivation of cytomegalovirus in patients with cirrhosis: analysis of 122 cases. Hepatology, 16(6): 1409-14, 1992
  2. Tanaka S, Toh Y, Mori R, Komori K, Okadome K, Sugimachi K. Possible role of cytomegalovirus in the pathogenesis of inflammatory aortic diseases. Journal of Vascular Surgery, 16(2): 274-9, 1992
pagetop